Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management

Wybrich R Cnossen, Joost P H Drenth, Wybrich R Cnossen, Joost P H Drenth

Abstract

Polycystic liver disease (PLD) is the result of embryonic ductal plate malformation of the intrahepatic biliary tree. The phenotype consists of numerous cysts spread throughout the liver parenchyma. Cystic bile duct malformations originating from the peripheral biliary tree are called Von Meyenburg complexes (VMC). In these patients embryonic remnants develop into small hepatic cysts and usually remain silent during life. Symptomatic PLD occurs mainly in the context of isolated polycystic liver disease (PCLD) and autosomal dominant polycystic kidney disease (ADPKD). In advanced stages, PCLD and ADPKD patients have massively enlarged livers which cause a spectrum of clinical features and complications. Major complaints include abdominal pain, abdominal distension and atypical symptoms because of voluminous cysts resulting in compression of adjacent tissue or failure of the affected organ. Renal failure due to polycystic kidneys and non-renal extra-hepatic features are common in ADPKD in contrast to VMC and PCLD. In general, liver function remains prolonged preserved in PLD. Ultrasonography is the first instrument to assess liver phenotype. Indeed, PCLD and ADPKD diagnostic criteria rely on detection of hepatorenal cystogenesis, and secondly a positive family history compatible with an autosomal dominant inheritance pattern. Ambiguous imaging or screening may be assisted by genetic counseling and molecular diagnostics. Screening mutations of the genes causing PCLD (PRKCSH and SEC63) or ADPKD (PKD1 and PKD2) confirm the clinical diagnosis. Genetic studies showed that accumulation of somatic hits in cyst epithelium determine the rate-limiting step for cyst formation. Management of adult PLD is based on liver phenotype, severity of clinical features and quality of life. Conservative treatment is recommended for the majority of PLD patients. The primary aim is to halt cyst growth to allow abdominal decompression and ameliorate symptoms. Invasive procedures are required in a selective patient group with advanced PCLD, ADPKD or liver failure. Pharmacological therapy by somatostatin analogues lead to beneficial outcome of PLD in terms of symptom relief and liver volume reduction.

Figures

Figure 1
Figure 1
Abdominal MRI and CT in patients with PLD. (A) Axial T1-weighted and (B) coronal T2-weighted MRI present 1 large cyst and numerous cystic nodules scattered at peripheral bile ducts. (C-D) CT-scanning in a PCLD patient presents multiple cysts originating from medium-sized bile ducts. (E-F) Co-occurrence of polycystic kidneys exists in ADPKD. Both PRKCSH and PKD2 gene mutations were predicted to be pathogenic (GRCh37-hg19; HGMD). Hepatic cysts are indicated by white arrows. (G) Diffuse VMC present numerous small-sized hepatic cysts located at peripheral branches of the biliary tree (in green). (H) The PLD phenotypes are arbitrarily staged and indicate disease progression. The disease course is progressive in a subset of severely affected PLD patients.
Figure 2
Figure 2
Comprehensive algorithm for diagnosis, management and genetic counseling in PCLD and ADPKD. The diagnostic criteria for PCLD and ADPKD compromises family history and age-related liver or kidney phenotype respectively [64,66]. PLD therapy is individually decided according to number, distribution and size of hepatic cysts [78]. Genetic counseling has an important role in symptomatic individuals with a positive family history for hepatic and/or renal cystogenesis in order to differentiate PLD and clinical management.
Figure 3
Figure 3
Intra-familial clinical heterogeneity in PCLD. Description of the data: (A) Pedigree of a PCLD family with PRKCSH gene mutation c.374_375delAG in affected individuals. The index patient (*) has 4 members with symptomatic PLD. Although the family history is positive, family members frequently are asymptomatic carriers or the liver phenotype remains unknown. (B) Axial CT-scanning, abdominal ultrasonography or MRI in 4 PCLD patients presented a variably number of hepatic cysts without renal disease.
Figure 4
Figure 4
Indications and considerations for treatment strategies in symptomatic PLD. Schematic overview of relevant indications and considerations in PLD management. Patient characteristics and liver phenotype such as severity of clinical symptoms, age, (surgical) history, degree of hepatomegaly, and number, size and location of hepatic cysts are essential parameters for this decision. In general, the choice of procedure is an individual process in consultation with the patient. Severely affected individuals are patients with massive hepatomegaly, refractory symptoms, PLD-related complications and/or end-stage liver failure. Care and follow-up of these patients should be managed with caution. *Notification: Results about treatment efficacy of prolonged or long-term somatostatin analogue use is unknown. **Arbitrary total liver volume (TLV), because this outcome measurement is related to other parameters such as height, total body surface and sex. ***For example: recurrent hepatic cyst infection, HVOO.

References

    1. Roskams T, Desmet V. Embryology of extra- and intrahepatic bile ducts, the ductal plate. Anat Rec (Hoboken) 2008;291:628–635.
    1. Raynaud P, Carpentier R, Antoniou A, Lemaigre FP. Biliary differentiation and bile duct morphogenesis in development and disease. Int J Biochem Cell Biol. 2011;43:245–256.
    1. Strazzabosco M, Fabris L. Development of the bile ducts: essentials for the clinical hepatologist. J Hepatol. 2012;56:1159–1170.
    1. Drenth JP, Chrispijn M, Bergmann C. Congenital fibrocystic liver diseases. Best Pract Res Clin Gastroenterol. 2010;24:573–584.
    1. Zheng RQ, Zhang B, Kudo M, Onda H, Inoue T. Imaging findings of biliary hamartomas. World J Gastroenterol. 2005;11:6354–6359.
    1. Raynaud P, Tate J, Callens C, Cordi S, Vandersmissen P, Carpentier R, Sempoux C, Devuyst O, Pierreux CE, Courtoy P, Dahan K, Delbecque K, Lepreux S, Pontoglio M, Guay-Woodford LM, Lemaigre FP. A classification of ductal plate malformations based on distinct pathogenic mechanisms of biliary dysmorphogenesis. Hepatology. 2011;53:1959–1966.
    1. Desmet VJ. Ludwig symposium on biliary disorders–part I. Pathogenesis of ductal plate abnormalities. Mayo Clin Proc. 1998;73:80–89.
    1. Hildebrandt F, Benzing T, Katsanis N. Ciliopathies. N Engl J Med. 2011;364:1533–1543.
    1. Mortele KJ, Ros PR. Cystic focal liver lesions in the adult: differential CT and MR imaging features. Radiographics. 2001;21:895–910.
    1. Salo J, Bru C, Vilella A, Gines P, Gilabert R, Castells A, Bruguera M, Rodes J. Bile-duct hamartomas presenting as multiple focal lesions on hepatic ultrasonography. Am J Gastroenterol. 1992;87:221–223.
    1. Lemaigre FP. Mechanisms of liver development: concepts for understanding liver disorders and design of novel therapies. Gastroenterology. 2009;137:62–79.
    1. Gunay-Aygun M. Liver and kidney disease in ciliopathies. Am J Med Genet C: Semin Med Genet. 2009;151C:296–306.
    1. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369:1287–1301.
    1. Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, Baumgarten DA, King BF Jr, Wetzel LH, Kenney PJ, Brummer ME, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP. Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol. 2006;1:64–69.
    1. Van Keimpema L, De Koning DB, Van Hoek B, Van Den Berg AP, Van Oijen MG, De Man RA, Nevens F, Drenth JP. Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver Int. 2011;31:92–98.
    1. Redston MS, Wanless IR. The hepatic von Meyenburg complex: prevalence and association with hepatic and renal cysts among 2843 autopsies [corrected] Mod Pathol. 1996;9:233–237.
    1. Brancatelli G, Federle MP, Vilgrain V, Vullierme MP, Marin D, Lagalla R. Fibropolycystic liver disease: CT and MR imaging findings. Radiographics. 2005;25(3):659–670.
    1. Karahan OI, Kahriman G, Soyuer I, Ok E. Hepatic von Meyenburg complex simulating biliary cystadenocarcinoma. Clin Imaging. 2007;31:50–53.
    1. Qian Q, Li A, King BF, Kamath PS, Lager DJ, Huston J 3rd, Shub C, Davila S, Somlo S, Torres VE. Clinical profile of autosomal dominant polycystic liver disease. Hepatology. 2003;37:164–171.
    1. Temmerman F, Missiaen L, Bammens B, Laleman W, Cassiman D, Verslype C, Van Pelt J, Nevens F. Systematic review: the pathophysiology and management of polycystic liver disease. Aliment Pharmacol Ther. 2011;34:702–713.
    1. Chapman AB. Cystic disease in women: clinical characteristics and medical management. Adv Ren Replace Ther. 2003;10:24–30.
    1. Sherstha R, McKinley C, Russ P, Scherzinger A, Bronner T, Showalter R, Everson GT. Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. Hepatology. 1997;26:1282–1286.
    1. Gabow PA, Johnson AM, Kaehny WD, Manco-Johnson ML, Duley IT, Everson GT. Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease. Hepatology. 1990;11:1033–1037.
    1. Pei Y. Diagnostic approach in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2006;1:1108–1114.
    1. Peters DJ, Breuning MH. Autosomal dominant polycystic kidney disease: modification of disease progression. Lancet. 2001;358:1439–1444.
    1. Macutkiewicz C, Plastow R, Chrispijn M, Filobbos R, Ammori BA, Sherlock DJ, Drenth JP, O’Reilly DA. Complications arising in simple and polycystic liver cysts. World J Hepatol. 2012;4:406–411.
    1. Hoevenaren IA, Wester R, Schrier RW, McFann K, Doctor RB, Drenth JP, Everson GT. Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease. Liver Int. 2008;28:264–270.
    1. Marion Y, Brevartt C, Plard L, Chiche L. Hemorrhagic liver cyst rupture: an unusual life-threatening complication of hepatic cyst and literature review. Ann Hepatol. 2013;12:336–339.
    1. Jouret F, Lhommel R, Devuyst O, Annet L, Pirson Y, Hassoun Z, Kanaan N. Diagnosis of cyst infection in patients with autosomal dominant polycystic kidney disease: attributes and limitations of the current modalities. Nephrol Dial Transplant. 2012;27:3746–3751.
    1. Waanders E, Van Keimpema L, Brouwer JT, Van Oijen MG, Aerts R, Sweep FC, Nevens F, Drenth JP. Carbohydrate antigen 19–9 is extremely elevated in polycystic liver disease. Liver Int. 2009;29:1389–1395.
    1. Kanaan N, Goffin E, Pirson Y, Devuyst O, Hassoun Z. Carbohydrate antigen 19–9 as a diagnostic marker for hepatic cyst infection in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2010;55:916–922.
    1. Akriviadis EA, Steindel H, Ralls P, Redeker AG. Spontaneous rupture of nonparasitic cyst of the liver. Gastroenterology. 1989;97:213–215.
    1. Uddin W, Ramage JK, Portmann B, Wilson P, Benjamin I, Tan KC, Williams R. Hepatic venous outflow obstruction in patients with polycystic liver disease: pathogenesis and treatment. Gut. 1995;36:142–145.
    1. Johnstone AJ, Turnbull LW, Allan PL, Garden OJ. Cholangitis and Budd Chiari syndrome as complications of simple cystic liver disease. HPB Surg. 1993;6:223–227. discussion 227–228.
    1. Torres VE, Rastogi S, King BF, Stanson AW, Gross JB Jr, Nogorney DM. Hepatic venous outflow obstruction in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1994;5:1186–1192.
    1. Grams J, Teh SH, Torres VE, Andrews JC, Nagorney DM. Inferior vena cava stenting: a safe and effective treatment for intractable ascites in patients with polycystic liver disease. J Gastrointest Surg. 2007;11:985–990.
    1. Chauveau D, Grunfeld JP, Durand F, Belghiti J. Ascites in a polycystic patient. Nephrol Dial Transplant. 1997;12:228–230.
    1. Lai EC, Wong J. Symptomatic nonparasitic cysts of the liver. World J Surg. 1990;14:452–456.
    1. Van Keimpema L, Nevens F, Adam R, Porte RJ, Fikatas P, Becker T, Kirkegaard P, Metselaar HJ, Drenth JP, European L. Intestine Transplant A: Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study. Transpl Int. 2011;24:1239–1245.
    1. Morgan DE, Lockhart ME, Canon CL, Holcombe MP, Bynon JS. Polycystic liver disease: multimodality imaging for complications and transplant evaluation. Radiographics. 2006;26:1655–1668. quiz 1655.
    1. Hateboer N, Dijk MA V, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, Torra R, Breuning M, Ravine D. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet. 1999;353:103–107.
    1. Chapman AB, Stepniakowski K, Rahbari-Oskoui F. Hypertension in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis. 2010;17:153–163.
    1. Torres VE, Chapman AB, Perrone RD, Bae KT, Abebe KZ, Bost JE, Miskulin DC, Steinman TI, Braun WE, Winklhofer FT, Hogan MC, Oskoui FR, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin DR, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Meyers CM, Schrier RW. HALT PKD Study Group. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int. 2012;81:577–585.
    1. Qian Q. Isolated polycystic liver disease. Adv Chronic Kidney Dis. 2010;17:181–189.
    1. Ecder T, Schrier RW. Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol. 2009;5:221–228.
    1. De Almeida EA, De Oliveira EI, Lopes JA, Almeida AG, Lopes MG, Prata MM. Diastolic function in several stages of chronic kidney disease in patients with autosomal dominant polycystic kidney disease: a tissue Doppler imaging study. Kidney Blood Press Res. 2007;30:234–239.
    1. Gevers TJ, De Koning DB, Van Dijk AP, Drenth JP. Low prevalence of cardiac valve abnormalities in patients with autosomal dominant polycystic liver disease. Liver Int. 2012;32:690–692.
    1. Timio M, Monarca C, Pede S, Gentili S, Verdura C, Lolli S. The spectrum of cardiovascular abnormalities in autosomal dominant polycystic kidney disease: a 10-year follow-up in a five-generation kindred. Clin Nephrol. 1992;37:245–251.
    1. Kato A, Takita T, Furuhashi M, Maruyama Y, Hishida A. Abdominal aortic aneurysms in hemodialysis patients with autosomal dominant polycystic kidney disease. Nephron. 2001;88:185–186.
    1. Schievink WI, Spetzler RF. Screening for intracranial aneurysms in patients with isolated polycystic liver disease. J Neurosurg. 1998;89:719–721.
    1. Pirson Y, Chauveau D, Torres V. Management of cerebral aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2002;13:269–276.
    1. Torra R, Nicolau C, Badenas C, Navarro S, Perez L, Estivill X, Darnell A. Ultrasonographic study of pancreatic cysts in autosomal dominant polycystic kidney disease. Clin Nephrol. 1997;47:19–22.
    1. Torra R, Sarquella J, Calabia J, Marti J, Ars E, Fernandez-Llama P, Ballarin J. Prevalence of cysts in seminal tract and abnormal semen parameters in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2008;3:790–793.
    1. Morris-Stiff G, Coles G, Moore R, Jurewicz A, Lord R. Abdominal wall hernia in autosomal dominant polycystic kidney disease. Br J Surg. 1997;84:615–617.
    1. Sharp CK, Zeligman BE, Johnson AM, Duley I, Gabow PA. Evaluation of colonic diverticular disease in autosomal dominant polycystic kidney disease without end-stage renal disease. Am J Kidney Dis. 1999;34:863–868.
    1. Drenth JP, Te Morsche RH, Smink R, Bonifacino JS, Jansen JB. Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease. Nat Genet. 2003;33:345–347.
    1. Li A, Davila S, Furu L, Qian Q, Tian X, Kamath PS, King BF, Torres VE, Somlo S. Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease. Am J Hum Genet. 2003;72:691–703.
    1. Davila S, Furu L, Gharavi AG, Tian X, Onoe T, Qian Q, Li A, Cai Y, Kamath PS, King BF, Azurmendi PJ, Tahvanainen P, Kääriäinen H, Höckerstedt K, Devuyst O, Pirson Y, Martin RS, Lifton RP, Tahvanainen E, Torres VE, Somlo S. Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet. 2004;36:575–577.
    1. Drenth JP, Martina JA, van de Kerkhof R, Bonifacino JS, Jansen JB. Polycystic liver disease is a disorder of cotranslational protein processing. Trends Mol Med. 2005;11:37–42.
    1. Janssen MJ, Waanders E, Woudenberg J, Lefeber DJ, Drenth JP. Congenital disorders of glycosylation in hepatology: the example of polycystic liver disease. J Hepatol. 2010;52:432–440.
    1. Waanders E, Te Morsche RH, De Man RA, Jansen JB, Drenth JP. Extensive mutational analysis of PRKCSH and SEC63 broadens the spectrum of polycystic liver disease. Hum Mutat. 2006;27:830.
    1. Rossetti S, Consugar MB, Chapman AB, Torres VE, Guay-Woodford LM, Grantham JJ, Bennett WM, Meyers CM, Walker DL, Bae K, Zhang QJ, Thompson PA, Miller JP, Harris PC. CRISP Consortium. Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2007;18:2143–2160.
    1. Waanders E, Venselaar H, Te Morsche RH, De Koning DB, Kamath PS, Torres VE, Somlo S, Drenth JP. Secondary and tertiary structure modeling reveals effects of novel mutations in polycystic liver disease genes PRKCSH and SEC63. Clin Genet. 2010;78:47–56.
    1. Reynolds DM, Falk CT, Li A, King BF, Kamath PS, Huston J 3rd, Shub C, Iglesias DM, Martin RS, Pirson Y, Torres VE, Somlo S. Identification of a locus for autosomal dominant polycystic liver disease, on chromosome 19p13.2-13.1. Am J Hum Genet. 2000;67:1598–1604.
    1. Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet. 1994;343:824–827.
    1. Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, Parfrey P, Cramer B, Coto E, Torra R, San Millan JL, Gibson R, Breuning M, Peters D, Ravine D. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2009;20:205–212.
    1. Ariza M, Alvarez V, Marin R, Aguado S, Lopez-Larrea C, Alvarez J, Menendez MJ, Coto E. A family with a milder form of adult dominant polycystic kidney disease not linked to the PKD1 (16p) or PKD2 (4q) genes. J Med Genet. 1997;34:587–589.
    1. Paterson AD, Pei Y. Is there a third gene for autosomal dominant polycystic kidney disease? Kidney Int. 1998;54:1759–1761.
    1. Daoust MC, Reynolds DM, Bichet DG, Somlo S. Evidence for a third genetic locus for autosomal dominant polycystic kidney disease. Genomics. 1995;25:733–736.
    1. Watnick TJ, Torres VE, Gandolph MA, Qian F, Onuchic LF, Klinger KW, Landes G, Germino GG. Somatic mutation in individual liver cysts supports a two-hit model of cystogenesis in autosomal dominant polycystic kidney disease. Mol Cell. 1998;2:247–251.
    1. Pei Y, Watnick T, He N, Wang K, Liang Y, Parfrey P, Germino G, St George-Hyslop P. Somatic PKD2 mutations in individual kidney and liver cysts support a “two-hit” model of cystogenesis in type 2 autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1999;10:1524–1529.
    1. Janssen MJ, Waanders E, Te Morsche RH, Xing R, Dijkman HB, Woudenberg J, Drenth JP. Secondary, somatic mutations might promote cyst formation in patients with autosomal dominant polycystic liver disease. Gastroenterology. 2011;141:2056–2063 e2052.
    1. Janssen MJ, Salomon J, Te Morsche RH, Drenth JP. Loss of heterozygosity is present in SEC63 germline carriers with polycystic liver disease. PLoS ONE. 2012;7:e50324.
    1. Bergmann C, Von Bothmer J, Ortiz Bruchle N, Venghaus A, Frank V, Fehrenbach H, Hampel T, Pape L, Buske A, Jonsson J, Sarioglu N, Santos A, Ferreira JC, Becker JU, Cremer R, Hoefele J, Benz MR, Weber LT, Buettner R, Zerres K. Mutations in multiple PKD genes may explain early and severe polycystic kidney disease. J Am Soc Nephrol. 2011;22:2047–2056.
    1. Nichols MT, Gidey E, Matzakos T, Dahl R, Stiegmann G, Shah RJ, Grantham JJ, Fitz JG, Doctor RB. Secretion of cytokines and growth factors into autosomal dominant polycystic kidney disease liver cyst fluid. Hepatology. 2004;40:836–846.
    1. Waanders E, Lameris AL, Op den Camp HJ, Pluk W, Gloerich J, Strijk SP, Drenth JP. Hepatocystin is not secreted in cyst fluid of hepatocystin mutant polycystic liver patients. J Proteome Res. 2008;7:2490–2495.
    1. Alvaro D, Onori P, Alpini G, Franchitto A, Jefferson DM, Torrice A, Cardinale V, Stefanelli F, Mancino MG, Strazzabosco M, Angelico M, Attili A, Gaudio E. Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease. Am J Pathol. 2008;172:321–332.
    1. Gevers TJ, Drenth JP. Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol. 2013;10:101–108.
    1. Tahvanainen E, Tahvanainen P, Kaariainen H, Hockerstedt K. Polycystic liver and kidney diseases. Ann Med. 2005;37:546–555.
    1. Rossetti S, Chauveau D, Kubly V, Slezak JM, Saggar-Malik AK, Pei Y, Ong AC, Stewart F, Watson ML, Bergstralh EJ, Winearls CG, Torres VE, Harris PC. Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype. Lancet. 2003;361:2196–2201.
    1. Luciano RL, Dahl NK. Extra-renal manifestations of ADPKD: considerations for routine screening and management. Nephrol Dial Transplant. 2014;29:247–254.
    1. Wijnands TF, Neijenhuis MK, Kievit W, Nevens F, Hogan MC, Torres VE, Gevers TJ, Drenth JP. Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume. Liver Int. 2013. doi:10.1111/liv.12430.
    1. Belibi FA, Wallace DP, Yamaguchi T, Christensen M, Reif G, Grantham JJ. The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2002;13:2723–2729.
    1. Drenth JP, Chrispijn M, Nagorney DM, Kamath PS, Torres VE. Medical and surgical treatment options for polycystic liver disease. Hepatology. 2010;52:2223–2230.
    1. Mudge DW, Taylor J, Bannister KM. Hepatic vein stenting for recurrent ascites in polycystic liver and kidney disease. Nephrol Dial Transplant. 2005;20:2566–2568.
    1. Chrispijn M, Nevens F, Gevers TJ, Vanslembrouck R, Van Oijen MG, Coudyzer W, Hoffmann AL, Dekker HM, De Man RA, Van Keimpema L, Drenth JP. The long-term outcome of patients with polycystic liver disease treated with lanreotide. Aliment Pharmacol Ther. 2012;35:266–274.
    1. Hogan MC, Masyuk TV, Page L, Holmes DR 3rd, Li X, Bergstralh EJ, Irazabal MV, Kim B, King BF, Glockner JF, Larusso NF, Torres VE. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant. 2012;27:3532–3539.
    1. Gevers TJ, Inthout J, Caroli A, Ruggenenti P, Hogan MC, Torres VE, Nevens F, Drenth JP. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gastroenterology. 2013;145:357–365. e351-352.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel